Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
131 hedge funds and large institutions have $1.54B invested in Aegerion Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 39 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
1% less call options, than puts
Call options by funds: $124M | Put options by funds: $125M
13% less funds holding
Funds holding: 150 → 131 (-19)
31% less capital invested
Capital invested by funds: $2.22B → $1.54B (-$676M)
38% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 39
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$111M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$101M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$54.8M |
| 4 |
PC
PointState Capital
New York
|
+$54.2M |
| 5 |
JP Morgan Chase
New York
|
+$38.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$62.5M |
| 2 |
HM
HealthCor Management
New York
|
-$48.4M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$37.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$31.8M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$29.5M |
AEGR Hedge Fund Activity: Q1 2014 in Review
131 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q1 2014, worth a combined $1.54B — down 31% from $2.22B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of AEGR and 24 opened new positions — a net loss of 15 holders — while 44 trimmed existing stakes and 56 added.
The largest buyer was Putnam Investments, adding an estimated $111M. The largest seller was Viking Global Investors, exiting entirely with an estimated $62.5M sold.
- 131 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q1 2014, down from 150 in Q4 2013.
- Funds reported $1.54B of Aegerion Pharmaceuticals stock for Q1 2014, down 31% quarter-over-quarter.
- 24 funds opened new Aegerion Pharmaceuticals positions in Q1 2014 and 39 closed out, a net change of -15 holders.
- The largest Aegerion Pharmaceuticals buyer in Q1 2014 was Putnam Investments, an estimated $111M added.
- The largest Aegerion Pharmaceuticals seller in Q1 2014 was Viking Global Investors, an estimated $62.5M sold.
Based on aggregated 13F filings for Q1 2014.